Repare Therapeutics

Biotech · Acquired

ATR kinase inhibitor (Camonsertib) and synthetic lethality platform for BRCA-mutant cancers

reparetx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
32
3 granted · 29 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3330ONCOSYNERGY, INC.—$27M
3331SOLUBLE THERAPEUTICS, INC.——
3332SIEYAX, INC——
3333Repare Therapeutics——
3334HOUSEY PHARMACEUTICAL RESEARCH LAB——
3335Alpha-9 Oncology——
3336ABBRATECH INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 32

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.